Synaps

Developing novel photodynamic therapies for neurosurgery

Synaps
  • About
    • Overview
    • Partnership >
      • Onco-THAI Inserm U1189
      • University of Lille
      • Lille University Hospital
      • Inserm
      • ECRIN
      • Leitat Technological Center
      • IDDI
      • Medical University of Graz
      • OP2
      • Erasme Hospital
  • Research
    • Overview
    • Clinical trial
    • Publications
  • Medical information
    • Overview
    • Glioblastoma
    • PhotoDynamic Therapies
  • News
  • Contact

  • About
    • Overview
    • Partnership >
      • Onco-THAI Inserm U1189
      • University of Lille
      • Lille University Hospital
      • Inserm
      • ECRIN
      • Leitat Technological Center
      • IDDI
      • Medical University of Graz
      • OP2
      • Erasme Hospital
  • Research
    • Overview
    • Clinical trial
    • Publications
  • Medical information
    • Overview
    • Glioblastoma
    • PhotoDynamic Therapies
  • News
  • Contact

Developing reproducible Photodynamic Therapies
​ to better treat glioblastoma

Photodynamic therapies
Copyright ONCO-THAI
Synaps gathers scientific and clinical teams in Europe, to enhance the treatment of glioblastomas using laser-based photodynamic therapies.
Photodynamic therapy (PDT) consists in exposing photosensitized tumour tissues to laser light, triggering the formation of molecules that kill malignant cells. This technology is potentially able to reach and selectively destroy tumour cells that cannot be removed through surgical resection. Beyond its efficacy, PDT is harmless for patient and thus deserves to be added in standard of care protocols.

Synaps: a research network to develop a new therapeutic approach

Despite demonstrating promising efficacy, PDT cannot be used today as a standard therapeutic modality because of the lack of reliable and reproducible therapy schemes, consensus on a photosentisizer and controlled multicentre clinical trial results.
Synaps brings together specialized research and clinical teams across Europe, to tackle these challenges and develop a promising therapy.
Picture
Université Lille 2
Onco Thai
Inserm
CHRU Lille
Picture
 Legal notice - Credits